Yayınlar & Eserler

Yayın Ağı
Makaleler 199
Tümü (199)
SCI-E, SSCI, AHCI (192)
SCI-E, SSCI, AHCI, ESCI (194)
ESCI (1)
Scopus (196)
TRDizin (9)
Diğer Yayınlar (2)

1. Long-term remission and monocyclic course in Still’s disease patients starting canakinumab early: data from the international AIDA network registry

Vitale A., Caggiano V., Sbalchiero J., Lopalco G., TUFAN A., Ragab G., et al.
Seminars in Arthritis and Rheumatism , cilt.80, 2026 (SCI-Expanded, Scopus)

2. Efficacy and safety of JAK inhibitors in Behçet syndrome: systematic literature review

Sulu B., ESATOĞLU S. N., Kurtulus-Erozkan G., Hatemi I., ÇELİK A. F., HATEMİ G.
Seminars in Arthritis and Rheumatism , cilt.80, 2026 (SCI-Expanded, Scopus)

3. Treat-to-target in Behçet syndrome

Bettiol A., Bertsias G., Bodaghi B., ÇELİK A. F., Fragoulis G. E., Saadoun D., et al.
Nature Reviews Rheumatology , cilt.22, sa.7, ss.459-470, 2026 (SCI-Expanded, Scopus)

4. EULAR recommendations for the management of Behçet’s syndrome: 2025 update

HATEMİ G., Ramiro S., ÖZGÜLER Y., ESATOĞLU S. N., Tomasson G., Barete S., et al.
Annals of the Rheumatic Diseases , cilt.85, sa.6, ss.1010-1025, 2026 (SCI-Expanded, Scopus)

5. Risk of intestinal involvement in mucocutaneous-onset Behçet’s disease: data from the AIDA network registry

Vitale A., Caggiano V., Sbalchiero J., Gavioli F., Lopalco G., Ragab G., et al.
Frontiers in Immunology , cilt.17, 2026 (SCI-Expanded, Scopus)

6. Prevalence of Latent and Active Tuberculosis Infection in Inflammatory Bowel Disease Patients Who Received Biological Treatment

DASHDAMIROVA S., EŞKAZAN T., ERZİN Y. Z., ÇELİK A. F., HATEMİ G., HATEMİ A. İ.
TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.37, sa.5, ss.564-572, 2026 (SCI-Expanded, Scopus, TRDizin) Creative Commons License Sürdürülebilir Kalkınma

7. ANCA-associated vasculitis presenting with tongue necrosis and severe gastrointestinal involvement

Karakoc A., Kopac S., Atas I., ERZİN Y. Z., EŞKAZAN T., Hatipoglu E., et al.
Clinical and Experimental Rheumatology , cilt.44, sa.4, ss.874-875, 2026 (SCI-Expanded, Scopus)

8. Turkish Society for Rheumatology recommendations for the diagnosis, follow-up and management of giant cell arteritis

ALİBAZ F., Kara M., ESATOĞLU S. N., KENAR ARTIN G., Uzun G. S., Ünlü B., et al.
Clinical and Experimental Rheumatology , cilt.44, sa.4, ss.647-662, 2026 (SCI-Expanded, Scopus)

9. The impact of demographics on organ damage in Behçet's syndrome: A cross-sectional analysis of the international PROBE cohort

Floris A., Laconi R., Chadli S., Laymouna A., Hegazy M. T., YAĞIZ ÖZOĞUL Y., et al.
Rheumatology , cilt.65, sa.2, 2026 (SCI-Expanded, Scopus)

10. Risk of major organ involvement in Behçet's patients with mucocutaneous onset: Data from the AIDA Network Registry

Vitale A., Gavioli F., Caggiano V., Sbalchiero J., Lopalco G., Ragab G., et al.
Rheumatology , cilt.65, sa.2, 2026 (SCI-Expanded, Scopus)

11. British Association of Dermatologists and British Society for Rheumatology living guideline for managing people with Behcets 2025

Murphy R., Moots R. J., Brogan P., ÇELİK A. F., Clement-Jones M., Forrest L., et al.
RHEUMATOLOGY , cilt.65, sa.2, 2026 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

12. Results from a pilot study of dusquetide for the treatment of aphthous ulcers associated with Behçet's syndrome

Donini O., Sulu B., Pullion C., Rumage A., Straube R., Schaber C., et al.
Rheumatology , cilt.65, sa.2, 2026 (SCI-Expanded, Scopus)

13. Efficacy and tolerability of switching from coated to compressed colchicine preparations in patients with Behçet’s syndrome

Fidan S., ESATOĞLU S. N., ÖZGÜLER Y., UĞURLU S., SEYAHİ E., MELİKOĞLU M., et al.
Rheumatology , cilt.65, sa.2, 2026 (SCI-Expanded, Scopus)

14. Elucidating the Role of Neutrophils in the Inflammatory Response to Behcet Syndrome

ÖZGÜLER Y., ESATOĞLU S. N., HATEMİ G.
Journal of Inflammation Research , cilt.19, 2026 (SCI-Expanded, Scopus) Creative Commons License

15. New insights into the management of Behçet syndrome

ESATOĞLU S. N., ÖZGÜLER Y., HATEMİ G.
Expert Opinion on Investigational Drugs , cilt.35, sa.5, ss.329-339, 2026 (SCI-Expanded, Scopus)

16. The Risk of Developing Ocular Involvement Among Behçet’s Disease Patients Presenting with Mucocutaneous Involvement at Disease Onset: Data from the International AIDA Network Behçet’s Disease Registry

Vitale A., Caggiano V., Sbalchiero J., Lopalco G., Ragab G., Guerriero S., et al.
Ophthalmology and Therapy , cilt.15, sa.1, ss.223-237, 2026 (SCI-Expanded, Scopus) Creative Commons License

17. British Association of Dermatologists and British Society for Rheumatology living guideline for managing people with Behçets 2025

Murphy R., Moots R. J., Brogan P., ÇELİK A. F., Clement-Jones M., Forrest L., et al.
British Journal of Dermatology , cilt.194, sa.1, 2026 (SCI-Expanded, Scopus)

18. Behcet's patient-derived HLA class I immunopeptidome is ERAP1-dependent and displays disease-specific candidate peptides

Haghighi Sabet A. B., Manches O., Aydin A. K., ÖZGÜLER Y., Yaylaz B. S., Workalemahu G., et al.
JOURNAL OF IMMUNOLOGY , cilt.214, 2025 (SCI-Expanded, Scopus)

19. Efficacy and Safety of JAK Inhibitors in Behcet's Syndrome: A Systematic Literature Review

Sulu B., ESATOĞLU S. N., HATEMİ A. İ., ÇELİK A. F., HATEMİ G.
ARTHRITIS & RHEUMATOLOGY , cilt.77, ss.421-422, 2025 (SCI-Expanded, Scopus)

20. Severe Visual Impairment in Behcet Syndrome in Time: A Comparison of Four Time Periods

ERDOĞAN M., Tascilar K., Ersoya Y., Ozcan A., Gurcan M., Ammar T., et al.
ARTHRITIS & RHEUMATOLOGY , cilt.77, ss.4937-4939, 2025 (SCI-Expanded, Scopus)

21. Diagnostic value of vein wall thickness measurement for patients with suspected Behcet syndrome

Bayraktar R. A., KAYADİBİ Y., Kahveci A., ESATOĞLU S. N., ADALETLİ İ., ÖZGÜLER Y., et al.
ARTHRITIS & RHEUMATOLOGY , cilt.77, ss.4939-4941, 2025 (SCI-Expanded, Scopus)

22. The Efficacy Of Targeted Therapies In Giant Cell Arteritis: A Systematic Review and Meta-Analysis

Kaymaz-Tahra S., Guneysu C. A., ESATOĞLU S. N., Uzun G. S., Ince B., Kara M., et al.
ARTHRITIS & RHEUMATOLOGY , cilt.77, ss.1485-1486, 2025 (SCI-Expanded, Scopus)

23. Factors associated with thrombosis in Behçet Syndrome: A systematic review and meta-analysis

Guzelant-Ozkose G., Yurttas B., ESATOĞLU S. N., AR M. C., Hamuryudan V., HATEMİ G.
Seminars in Arthritis and Rheumatism , cilt.73, 2025 (SCI-Expanded, Scopus)

24. Variability in phenotype clusters of Behçet's syndrome: A systematic review

Macit B., ESATOĞLU S. N., Akyuz-Yesilyurt K., HATEMİ G.
Seminars in Arthritis and Rheumatism , cilt.73, 2025 (SCI-Expanded, Scopus)

25. De novo manifestations during adalimumab treatment in Behçet's syndrome

ESATOĞLU S. N., SÖNMEZ Ö., UÇAR D., Kaymaz E., ÖZGÜLER Y., UĞURLU S., et al.
RHEUMATOLOGY , cilt.64, sa.4, ss.2034-2040, 2025 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

26. Influence of gender on Behçet's disease phenotype and irreversible organ damage: Data from the International AIDA Network Behçet's Disease Registry

Sota J., Ragab G., AlMaglouth I., Lopalco G., TUFAN A., DİRESKENELİ R. H., et al.
Joint Bone Spine , cilt.92, sa.2, 2025 (SCI-Expanded, Scopus)

27. Development of Posterior Uveitis in Behçet Syndrome Patients with Vitreous Cells at Baseline

Uçar D., Bircan B. E., Rustamli N., Batu Oto B., Hamuryudan V., Hatemi G., et al.
Ocular Immunology and Inflammation , cilt.33, sa.2, ss.243-249, 2025 (SCI-Expanded, Scopus)

28. New and future perspectives in Behçet's syndrome

Sulu B., Hatemi G.
ARCHIVES OF RHEUMATOLOGY , cilt.39, sa.4, ss.511-521, 2024 (SCI-Expanded, Scopus, TRDizin)

29. Mimickers of nervous system involvement among patients with Behçet's syndrome

Nas E. D., ÇALIŞKAN E., Gulec Z. E., UYGUNOĞLU U., Tutuncu M., Saip S., et al.
JOURNAL OF NEUROLOGY , cilt.271, sa.10, ss.6903-6911, 2024 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

30. Behçet’s syndrome: one year in review 2024

Hatemi G., Seyahi E., Fresko İ., Talarico R., Uçar D., Hamuryudan V.
Clinical and Experimental Rheumatology , cilt.42, sa.10, ss.1999-2007, 2024 (SCI-Expanded, Scopus) Creative Commons License

31. Tocilizumab may not be a good option for vascular involvement due to Behçet's syndrome.

Ozdede A., ESATOĞLU S. N., Durmaz E. Ş., Karakoc A., Ogun H., HATEMİ G., et al.
Clinical and experimental rheumatology , cilt.42, sa.10, ss.2057-2064, 2024 (SCI-Expanded, Scopus)

32. Behcet's Disease Immune Landscape Exhibits a Universal NFkB-mediated Hyperactivation Pattern with Cell-specific TNFAIP3 Responses and a Superimposed IFN-regulated Endotype

Özgüler Y., Manches O., Uçar D., Lin Z., Khodadadi-Jamayran A., Tsirigos A., et al.
ARTHRITIS & RHEUMATOLOGY , ss.5125, 2024 (SCI-Expanded, Scopus)

33. Skin Microbiome Shows Differences Between Pathergy Positive and Negative Patients with Behcet's Syndrome

Sarac B., KALKANCI A., KILIÇ E., ŞAHİN E. A., ÖZGÜLER Y., HATEMİ G.
ARTHRITIS & RHEUMATOLOGY , ss.5124, 2024 (SCI-Expanded, Scopus)

34. Screening for pulmonary arterial hypertension in patients with systemic sclerosis in the era of new pulmonary arterial hypertension definitions

ERDOĞAN M., Kilickiran Avci B., Ebren C., Ersoy Y., Ongen Z., Ongen G., et al.
Clinical and Experimental Rheumatology , cilt.42, sa.8, ss.1590-1597, 2024 (SCI-Expanded, Scopus) Creative Commons License

35. Validation of the Behçet's Syndrome Overall Damage Index (BODI) for retrospective studies and a proposal for modification

Ozogul Y. Y., ÖZGÜLER Y., ESATOĞLU S. N., UÇAR D., UYGUNOĞLU U., KUTLUBAY Z., et al.
RHEUMATOLOGY , 2024 (SCI-Expanded, Scopus)

36. Treatment of pulmonary arterial hypertension in patients with connective tissue diseases: a systematic review and meta-analysis.

ERDOĞAN M., ESATOĞLU S. N., Kilickiran Avci B., HATEMİ G.
Internal and emergency medicine , cilt.19, sa.3, ss.731-743, 2024 (SCI-Expanded, Scopus) Creative Commons License

37. A Proposal of a New Tool for the Assessment of Damage in Behçet Syndrome Uveitis: Cerrahpasa Ocular Damage Grading System

Ozyazgan Y., UÇAR D., BATU OTO B., ESATOĞLU S. N., ÖZGÜLER Y., HATEMİ G., et al.
Ocular Immunology and Inflammation , cilt.32, sa.10, ss.2332-2338, 2024 (SCI-Expanded, Scopus)

38. Mycophenolate mofetil may be an alternative for maintenance therapy of Behçet syndrome uveitis: a single-center retrospective analysis

UÇAR D., ESATOĞLU S. N., Cerme E., BATU OTO B., Hamuryudan V., SEYAHİ E., et al.
Rheumatology International , cilt.43, sa.11, ss.2099-2106, 2023 (SCI-Expanded, Scopus)

39. De Novo Manifestations During Adalimumab Treatment in Behcet Syndrome

ESATOĞLU S. N., SÖNMEZ Ö., UÇAR D., Kaymaz E., ÖZGÜLER Y., UĞURLU S., et al.
ARTHRITIS & RHEUMATOLOGY , ss.3070-3072, 2023 (SCI-Expanded, Scopus)

40. Abdominal Surgical Interventions Among Patients with Gastrointestinal Involvement of Behcet Syndrome

ESATOĞLU S. N., GÜNER S., Guler S., HATEMİ G., KEPİL N., ERZİN Y. Z., et al.
ARTHRITIS & RHEUMATOLOGY , ss.3068-3070, 2023 (SCI-Expanded, Scopus)

41. Treatment of Pulmonary Arterial Hypertension in Patients with Connective Tissue Diseases: A Meta-analysis

Erdogan M., ESATOĞLU S. N., KILIÇKIRAN AVCI B., HATEMİ G.
ARTHRITIS & RHEUMATOLOGY , ss.3001-3003, 2023 (SCI-Expanded, Scopus)

42. Central Nervous System Involvement and Mimickers in ANCA Associated Vasculitis

Ozogul Y. Y., ESATOĞLU S. N., Ozogul M., KIZILKILIÇ O., ÖZGÜLER Y., Uygunoglu U., et al.
ARTHRITIS & RHEUMATOLOGY , ss.3063-3065, 2023 (SCI-Expanded, Scopus)

43. Development of Posterior Uveitis in Behcet's Syndrome Patients with Vitreous Cells Without Any Other Posterior Involvement

UÇAR D., Bircan B. E., RUSTAMLI N., BATU OTO B., HAMURYUDAN V., ESATOĞLU S. N., et al.
ARTHRITIS & RHEUMATOLOGY , ss.3072-3073, 2023 (SCI-Expanded, Scopus)

44. Axial Spondyloarthritis in Patients with Gastrointestinal Involvement of Behcet Syndrome

ÖZTÜRK M., ESATOĞLU S. N., HATEMİ A. İ., ÇELİK A. F., KARGIN O. A., ÖZ A., et al.
ARTHRITIS & RHEUMATOLOGY , ss.3067-3068, 2023 (SCI-Expanded, Scopus)

45. Behcet's Disease-Associated TCR in the Eye Points to HLA Class I-Restricted Autoimmunity

Nowatzky J., Lin Z., Ozguler Y., Khodadadi-Jamayran A., UÇAR D., Tsirigos A., et al.
ARTHRITIS & RHEUMATOLOGY , ss.1376, 2023 (SCI-Expanded, Scopus)

46. Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet’s Syndrome

Mease P. J., HATEMİ G., Paris M., Cheng S., Maes P., Zhang W., et al.
American Journal of Clinical Dermatology , cilt.24, sa.5, ss.809-820, 2023 (SCI-Expanded, Scopus) Creative Commons License

47. Treatment of systemic sclerosis-associated digital ulcers: recommendations of the Turkish Society for Rheumatology

Karadag D. T., Yalcinkaya Y., AKDOĞAN A., Avanoglu A., Bes C., BİRLİK A. M., et al.
Clinical and Experimental Rheumatology , cilt.41, sa.8, ss.1679-1687, 2023 (SCI-Expanded, Scopus)

48. Behcet Syndrome

HATEMİ G., Ucar D., Uygunoglu U., Yazici H., Yazici Y.
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA , cilt.49, sa.3, ss.585-602, 2023 (SCI-Expanded, Scopus)

49. Therapeutic approach to central nervous system involvement of Behçet's disease

Sota J., Capuano A., Emmi G., Iannone F., Cantarini L., HATEMİ G., et al.
Seminars in Arthritis and Rheumatism , cilt.61, 2023 (SCI-Expanded, Scopus)

50. Conventional and molecular cytogenetic analyses in Behçet’s syndrome patients with gastrointestinal involvement

Esatoğlu S. N., Yılmaz Ş., Hatemi G., Kuru R. D., Çırakoğlu A., Hatemi A. İ., et al.
Ulusal Romatoloji Dergisi , cilt.15, sa.2, ss.95-101, 2023 (Scopus, TRDizin)

51. Sistemik lupus eritematozusda plazma değişim tedavisi: Tek merkez retrospektif kohort çalışması

Özgüler Y., Ak T., Esatoğlu S. N., Elverdi T., Eşkazan A. E., Uğurlu S., et al.
Ulusal Romatoloji Dergisi , cilt.15, sa.2, ss.89-94, 2023 (TRDizin)

52. Difficult-to-treat Beh?et syndrome: A therapeutic approach

Yazici Y., HATEMİ G.
CLINICAL IMMUNOLOGY , cilt.249, 2023 (SCI-Expanded, Scopus)

53. Musculoskeletal manifestations in children with Behcet's syndrome: data from the AIDA Network Behcet's Syndrome Registry

Gaggiano C., Maselli A., Sfikakis P. P., Laskari K., Ragab G., Hegazy M. T., et al.
INTERNAL AND EMERGENCY MEDICINE , cilt.18, sa.3, ss.743-754, 2023 (SCI-Expanded, Scopus) Creative Commons License

54. Treat to target in Behcet's disease: Should we follow the paradigm of other systemic rheumatic diseases?

Fragoulis G. E., Bertsias G., Bodaghi B., GÜL A., van Laar J., MUMCU G., et al.
Clinical Immunology , cilt.246, 2023 (SCI-Expanded, Scopus)

55. Heat Shock Proteins in Behçet Syndrome

Aydın A. K. K., HATEMİ G.
Balkan Medical Journal , cilt.40, sa.5, ss.314-323, 2023 (SCI-Expanded, Scopus) Creative Commons License

56. A patient-driven registry on Behçet’s disease: the AIDA for patients pilot project

Gaggiano C., Del Bianco A., Sota J., Gentileschi S., Ruscitti P., Giacomelli R., et al.
Frontiers in Medicine , cilt.10, 2023 (SCI-Expanded, Scopus) Creative Commons License

57. ANCA ile ilişkili vaskülitte plazma değişim tedavisi: Tek merkez retrospektif kohort çalışması

Özgüler Y., Ak T., Esatoğlu S. N., Elverdi T., Eşkazan A. E., Uğurlu S., et al.
Ulusal Romatoloji Dergisi , cilt.14, sa.3, ss.131-136, 2022 (Scopus, TRDizin)

58. Frequency of AA amyloidosis has decreased in Behcet's syndrome: a retrospective study with long-term follow-up and a systematic review Amyloidosis in Behcet's syndrome

Karatemiz G., ESATOĞLU S. N., Gurcan M., ÖZGÜLER Y., YURDAKUL S., HAMURYUDAN V., et al.
RHEUMATOLOGY , cilt.62, sa.1, ss.9-18, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

59. Behcet's disease risk-variant HLA-B51/ERAP1-Hap10 alters human CD8 T cell immunity

Cavers A., Kugler M. C., Ozguler Y., Al-Obeidi A. F., HATEMİ G., Ueberheide B. M., et al.
ANNALS OF THE RHEUMATIC DISEASES , cilt.81, sa.11, ss.1603-1611, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

60. Development and implementation of the AIDA International Registry for patients with Behcet's disease

Vitale A., Della Casa F., Ragab G., Almaghlouth I. A., Lopalco G., Pereira R. M., et al.
INTERNAL AND EMERGENCY MEDICINE , cilt.17, sa.7, ss.1977-1986, 2022 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma

61. Dissection of Ocular and Peripheral Blood Immune Phenotypes Suggests Preferential Transmigration of CD16+ Monocytes to Effector Sites in Behcet's Disease

Ozguler Y., Lin Z., Cavers A., HATEMİ G., Manches O., Nowatzky J.
ARTHRITIS & RHEUMATOLOGY , ss.3097, 2022 (SCI-Expanded, Scopus)

62. Validation of Behcet's Disease Overall Damage Index (BODI) for Retrospective Studies and a Proposal for Modification

Ozogul Y. Y., Ozguler Y., UÇAR D., Uygunoglu U., Kutlubay Z., Hamuryudan V., et al.
ARTHRITIS & RHEUMATOLOGY , ss.3091-3092, 2022 (SCI-Expanded, Scopus)

63. Development of Posterior Uveitis in Behcet's Syndrome Patients with Vitreous Cells Without Any Other Posterior Involvement

UÇAR D., Bircan B. E., RUSTAMLI N., BATU OTO B., HAMURYUDAN V., ESATOĞLU S. N., et al.
ARTHRITIS & RHEUMATOLOGY , ss.3090-3091, 2022 (SCI-Expanded, Scopus)

64. Outcome of Vascular Involvement of Behcet Syndrome Treated with Infliximab: A Retrospective Cohort Study

HATEMİ G., TÜKEK N. B., ESATOĞLU S. N., ÖZGÜLER Y., Taflan S. S., MELİKOĞLU M., et al.
ARTHRITIS & RHEUMATOLOGY , ss.3098-3099, 2022 (SCI-Expanded, Scopus)

65. Emergence of new manifestations during infliximab treatment in Behcet's syndrome

Tukek N. B., Esatoglu S. N., HATEMİ G., Caliskan E. B., Ozyazgan Y., Ucar D., et al.
RHEUMATOLOGY , cilt.61, sa.9, ss.3746-3753, 2022 (SCI-Expanded, Scopus)

66. Screening for latent tuberculosis before starting TNF-alpha inhibitors in a population with high BCG vaccination rates

Hacioglu A., Borekci Ş., Melikoglu M., Ozguler Y., Esatoglu S. N., Ugurlu S., et al.
Rheumatology International , cilt.42, sa.8, ss.1443-1451, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

67. Frequency and severity of COVID-19 in patients with various rheumatic diseases treated regularly with colchicine or hydroxychloroquine

ÖZTAŞ M., BEKTAŞ M., KARACAN İ., Aliyeva N., DAĞ A., Aghamuradov S., et al.
JOURNAL OF MEDICAL VIROLOGY , cilt.94, sa.7, ss.3431-3437, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

68. Development and Implementation of the AIDA International Registry for Patients With VEXAS Syndrome

Vitale A., Caggiano V., Della Casa F., Hernandez-Rodriguez J., Frassi M., Monti S., et al.
FRONTIERS IN MEDICINE , cilt.9, 2022 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma

69. Impact of apremilast on quality of life in Behcet's syndrome: analysis of the phase 3 RELIEF study

HATEMİ G., Mahr A., Takeno M., Kim D., MELİKOĞLU M., Cheng S., et al.
RMD OPEN , cilt.8, sa.2, 2022 (SCI-Expanded, Scopus) Creative Commons License

70. Core Set of Domains for Outcome Measures in Behcet's Syndrome

HATEMİ G., Meara A., ÖZGÜLER Y., DİRESKENELİ R. H., Mahr A., Shea B., et al.
ARTHRITIS CARE & RESEARCH , cilt.74, ss.691-699, 2022 (SCI-Expanded, Scopus) Creative Commons License

71. Challenges in optimising patient participation in research: do patients participating in meetings represent the actual patient population with Behcet's syndrome?

Taflan S. S., ESATOĞLU S. N., ÖZGÜLER Y., YURTTAŞ B., MELİKOĞLU M., HATEMİ G.
ANNALS OF THE RHEUMATIC DISEASES , cilt.81, ss.448-450, 2022 (SCI-Expanded, Scopus)

72. Global epidemiology of vasculitis

Watts R. A., HATEMİ G., Burns J. C., Mohammad A. J.
NATURE REVIEWS RHEUMATOLOGY , cilt.18, sa.1, ss.22-34, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

73. The incidence, clinical characteristics, and outcome of COVID-19 in a prospectively followed cohort of patients with Behcet's syndrome

Ozcifci G., Aydin T., Atli Z., BALKAN İ. İ., TABAK Ö. F., ÖZTAŞ M., et al.
RHEUMATOLOGY INTERNATIONAL , cilt.42, sa.1, ss.101-113, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

74. Takayasu arteritis.

Esatoglu S. N., Hatemi G.
Current opinion in rheumatology , cilt.34, sa.1, ss.18-24, 2022 (SCI-Expanded, Scopus)

75. A treat-to-target approach is needed for Behçet's syndrome.

Hatemi G.
Current opinion in rheumatology , cilt.34, sa.1, ss.39-45, 2022 (SCI-Expanded, Scopus)

76. Behcet syndrome

Yazici Y., HATEMİ G., Bodaghi B., Cheon J. H., Suzuki N., Ambrose N., et al.
NATURE REVIEWS DISEASE PRIMERS , cilt.7, sa.1, 2021 (SCI-Expanded, Scopus)

77. COVID-19 Among Patients With Inflammatory Rheumatic Diseases

Esatoglu S. N., Tascilar K., Babaoglu H., Bes C., YURTTAŞ B., AKAR S., et al.
FRONTIERS IN IMMUNOLOGY , cilt.12, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

78. Aortic involvement in relapsing polychondritis: case-based review.

Erdogan M., Esatoglu S. N., Hatemi G., Hamuryudan V.
Rheumatology international , cilt.41, sa.4, ss.827-837, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

79. Apremilast for oral ulcers associated with active Behçet's syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial.

Hatemi G., Mahr A., Takeno M., Kim D. Y., Saadoun D., DİRESKENELİ R. H., et al.
Clinical and experimental rheumatology , cilt.39, sa.5, 2021 (SCI-Expanded, Scopus)

80. An evaluation of apremilast for the treatment of adult patients with oral ulcers associated with Behcet's syndrome

Ozdede A., HATEMİ G.
EXPERT OPINION ON PHARMACOTHERAPY , cilt.22, ss.1533-1537, 2021 (SCI-Expanded, Scopus)

81. Recent Insights into the Management of Behcet Syndrome

Ozguler Y., Ozdede A., HATEMİ G.
JOURNAL OF INFLAMMATION RESEARCH , cilt.14, ss.3429-3441, 2021 (SCI-Expanded, Scopus)

82. One year in review 2021: Behçet's syndrome.

Hatemi G., SEYAHİ E., Fresko I., Talarico R., Ucar D., Hamuryudan V.
Clinical and experimental rheumatology , cilt.39, sa.5, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

83. Immunogenicity of Infliximab Among Patients With Behçet Syndrome: A Controlled Study.

Esatoglu S. N., Akkoc-Mustafayev F. N., Ozguler Y., Ozbakır F., NOHUT O. K., Cevirgen D., et al.
Frontiers in immunology , cilt.11, ss.618973, 2020 (SCI-Expanded, Scopus)

84. Clinical Features and Outcomes of Patients with Granulomatosis with Polyangiitis and Review of Literature

ARSLAN E., Oruc M., Yalin S. F., Alagoz S., Demir H., HATEMİ G., et al.
TURKISH JOURNAL OF NEPHROLOGY , cilt.29, sa.4, ss.279-288, 2020 (ESCI, Scopus, TRDizin)

85. One year in review 2020: Behçet's syndrome

Hatemi G., Seyahi E., Fresko İ., Talarico R., HAMURYUDAN V.
Clinical and experimental rheumatology , cilt.38, sa.5, ss.3-10, 2020 (SCI-Expanded, Scopus)

86. Long term follow-up of Behçet's syndrome patients treated with cyclophosphamide.

Gurcan M., Esatoglu S. N., Hamuryudan V., Saygin D., Ugurlu S., Seyahi E., et al.
Rheumatology (Oxford, England) , cilt.59, sa.9, ss.2264-2271, 2020 (SCI-Expanded, Scopus)

87. Disease course and healthcare costs of a cohort of rheumatoid arthritis patients from Turkey

Ayan G., Esatoglu S. N., Hatemi G., HAMURYUDAN V.
RHEUMATOLOGY INTERNATIONAL , cilt.40, sa.7, ss.1037-1044, 2020 (SCI-Expanded, Scopus)

88. How to treat myelodysplastic syndrome with clinical features resembling Behcet syndrome: a case-based systematic review

Yilmaz U., Ar M. C., Esatoglu S. N., Bavunoglu I., Erzin Y. Z., Hatemi A. İ., et al.
ANNALS OF HEMATOLOGY , sa.6, ss.1193-1203, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

89. Clinical course of acute deep vein thrombosis of the legs in Behçet's syndrome

Ozguler Y., Hatemi G., Cetinkaya F., Tascilar K., Hamuryudan V., Ugurlu S., et al.
Rheumatology (United Kingdom) , cilt.59, sa.4, ss.799-806, 2020 (SCI-Expanded, Scopus)

90. Comment on: Clinical course of acute deep vein thrombosis of the legs in Behçet's syndrome: Reply

Ozguler Y., Hatemi G., Cetinkaya F., Tascilar K., Hamuryudan V., Ugurlu S., et al.
Rheumatology (United Kingdom) , cilt.59, sa.4, ss.914-915, 2020 (SCI-Expanded, Scopus)

91. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis

Hellmich B., Agueda A., Monti S., Buttgereit F., de Boysson H., Brouwer E., et al.
ANNALS OF THE RHEUMATIC DISEASES , cilt.79, sa.1, ss.19-30, 2020 (SCI-Expanded, Scopus)

92. Treating the Different Phenotypes of Behcet's Syndrome

Bettiol A., HATEMİ G., Vannozzi L., Barilaro A., Prisco D., Emmi G.
FRONTIERS IN IMMUNOLOGY , cilt.10, 2019 (SCI-Expanded, Scopus) Creative Commons License

93. The improper use of a no-treatment group in the randomised surgical trial for subacromial shoulder pain.

Guzelant G., Hatemi G.
Clinical and experimental rheumatology , ss.9, 2019 (SCI-Expanded, Scopus)

94. Bone marrow oedema on sacroiliac/spine MRI: is it really a sign of objective inflammation warranting treatment?

Esatoglu S. N., Hatemi G.
Clinical and experimental rheumatology , sa.6, ss.10, 2019 (SCI-Expanded, Scopus)

95. Tapering tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective study.

Hacioglu A., Hatemi G., Esatoglu S. N., Hamuryudan V.
Clinical and experimental rheumatology , sa.6, ss.8, 2019 (SCI-Expanded, Scopus)

96. One year in review 2019: Behçet's syndrome

Hatemi G., Seyahi E., Fresko İ., Talarico R., Hamuryudan V.
Clinical and experimental rheumatology , cilt.37, sa.6, ss.3-17, 2019 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

97. Disease Course of Behcet's Syndrome Patients Not Fulfilling International Study Group Criteria at Presentation

Esatoglu S. N., Bilgin S., Sulu C., Hamuryudan V., Kutlubay Z., MELİKOĞLU M., et al.
ARTHRITIS & RHEUMATOLOGY , cilt.71, 2019 (SCI-Expanded, Scopus)

98. Pentoxifylline Gel for Oral Ulcers in Patients with Behcet's Syndrome

HATEMİ G., Yurttas B., Kutlubay Z., Cote T., Derkunt S. B., Yazici Y., et al.
ARTHRITIS & RHEUMATOLOGY , cilt.71, 2019 (SCI-Expanded, Scopus)

99. Acknowledged statistical help and a better use of p values: a proposal.

Dincses E., Guzelant G., Hatemi G., Sut N., Yazici H.
Clinical and experimental rheumatology , cilt.37, sa.5, ss.855-857, 2019 (SCI-Expanded, Scopus)

100. Update on Outcome Measure Development in Large-vessel Vasculitis: Report from OMERACT 2018

Aydin S. Z., Robson J. C., Sreih A. G., Hill C., Alibaz-Oner F., Mackie S., et al.
JOURNAL OF RHEUMATOLOGY , cilt.46, sa.9, ss.1198-1201, 2019 (SCI-Expanded, Scopus) Creative Commons License

101. Update on the treatment of Behcet's syndrome

ESATOĞLU S. N., HATEMİ G.
INTERNAL AND EMERGENCY MEDICINE , cilt.14, sa.5, ss.661-675, 2019 (SCI-Expanded, Scopus)

102. Behcet's Syndrome as a Model of Thrombo-Inflammation: The Role of Neutrophils

Emmi G., Becatti M., Bettiol A., HATEMİ G., Prisco D., Fiorillo C.
FRONTIERS IN IMMUNOLOGY , cilt.10, 2019 (SCI-Expanded, Scopus) Creative Commons License

103. Management of skin, mucosa and joint involvement of Behçet's syndrome: A systematic review for update of the EULAR recommendations for the management of Behçet's syndrome.

Leccese P., Ozguler Y., Christensen R., Esatoglu S. N., Bang D., Bodaghi B., et al.
Seminars in arthritis and rheumatism , cilt.48, sa.4, ss.752-762, 2019 (SCI-Expanded, Scopus)

104. Management of large-vessel vasculitis

Salvarani C., HATEMİ G.
CURRENT OPINION IN RHEUMATOLOGY , cilt.31, sa.1, ss.25-31, 2019 (SCI-Expanded, Scopus)

105. Patients' experiences with Behcet's syndrome: structured interviews among patients with different types of organ involvement

Ozguler Y., Merkel P. A., Gurcan M., Bocage C., Eriksen W., Kutlubay Z., et al.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY , cilt.37, sa.6, ss.28-34, 2019 (SCI-Expanded, Scopus)

106. Biosimilar infliximab for Behcet's syndrome: a case series

Dincses E., Esatoglu S. N., Ozguler Y., Uygunoglu U., Hamuryudan V., Seyahi E., et al.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY , cilt.37, sa.6, ss.111-115, 2019 (SCI-Expanded, Scopus)

107. Management of major organ involvement of Behçet's syndrome: a systematic review for update of the EULAR recommendations.

Ozguler Y., Leccese P., Christensen R., Esatoglu S. N., Bang D., Bodaghi B., et al.
Rheumatology (Oxford, England) , cilt.57, sa.12, ss.2200-2212, 2018 (SCI-Expanded, Scopus)

108. Highlights of the 18th International Conference on Behçet's syndrome

ESATOĞLU S. N., Kutlubay Z., HATEMİ G.
Clinical and experimental rheumatology , cilt.36, sa.6, ss.3-12, 2018 (SCI-Expanded, Scopus)

109. Faecal but not serum calprotectin levels look promising in predicting active disease in Behçet's syndrome patients with gastrointestinal involvement

Esatoglu S. N., Hatemi I., Ozguler Y., Hatemi G., Uzun H., Celik A. F., et al.
Clinical and experimental rheumatology , cilt.36, sa.6, ss.90-96, 2018 (SCI-Expanded, Scopus)

110. Efficacy of Apremilast for Oral Ulcers Associated with Active Behcet's Syndrome over 28 Weeks: Results from a Phase III Study

Hatemi G., Mahr A., Ishigatsubo Y., Song Y. W., Melikoglu M., Cheng S., et al.
ARTHRITIS & RHEUMATOLOGY , cilt.70, 2018 (SCI-Expanded, Scopus)

111. Acknowledged Biostatistical Help and the Quality of Statistical Analyses in Randomized Controlled Trials in Rheumatology

Dincses E., Guzelant G., Hatemi G., Yazici H.
ARTHRITIS & RHEUMATOLOGY , cilt.70, 2018 (SCI-Expanded, Scopus)

112. Efficacy of Apremilast for Oral Ulcers Associated with Active Behcet's Syndrome in a Phase III Study: A Prespecified Analysis By Baseline Patient Demographics and Disease Characteristics

Hatemi G., Mahr A., Takeno M., Kim D., Melikoglu M., Cheng S., et al.
ARTHRITIS & RHEUMATOLOGY , cilt.70, 2018 (SCI-Expanded, Scopus)

113. Retrospective Analysis of Initial Presentation Findings of Behcet's Syndrome throughout 4 Decades

Dincses E., Ozguler Y., Ucar D., Ozyazgan Y., Ugurlu S., Hatemi G., et al.
ARTHRITIS & RHEUMATOLOGY , cilt.70, 2018 (SCI-Expanded, Scopus)

114. Assessing the possible association of anti-TNF use with new malignancies: A neglected methodological consideration.

Ozguler Y., Yazici Y., Hatemi G., Tascilar K., Yazici H.
Pharmacoepidemiology and drug safety , cilt.27, sa.8, ss.894-901, 2018 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

115. 2018 update of the EULAR recommendations for the management of Behçet's syndrome.

Hatemi G., Christensen R., Bang D., Bodaghi B., Celik A. F., Fortune F., et al.
Annals of the rheumatic diseases , cilt.77, sa.6, ss.808-818, 2018 (SCI-Expanded, Scopus)

116. Rituximab for anti-neutrophil cytoplasmic antibodies-associated vasculitis: experience of a single center and systematic review of non-randomized studies

Ayan G., Esatoglu S. N., Hatemi G., Ugurlu S., Seyahi E., Melikoglu M., et al.
RHEUMATOLOGY INTERNATIONAL , cilt.38, sa.4, ss.607-622, 2018 (SCI-Expanded, Scopus)

117. Türkiye romatoloji derneği aksiyel spondiloartrit ulusal tedavi önerileri

HATEMİ G., AKAR S., AKDOĞAN A., ATAGÜNDÜZ M. P., ersözlü e. d., ESATOĞLU S. N., et al.
Ulusal romatoloji dergisi , 2018 (Hakemli Dergi)

118. Behcet syndrome: a contemporary view

Yazici H., Seyahi E., Hatemi G., Yazici Y.
NATURE REVIEWS RHEUMATOLOGY , cilt.14, sa.2, ss.107-119, 2018 (SCI-Expanded, Scopus)

119. Gastrointestinal Involvement in Behcet Disease

Hatemi I., Hatemi G., Celik A. F.
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA , cilt.44, sa.1, ss.45-65, 2018 (SCI-Expanded, Scopus)

120. türkiye romatoloji derneği aksiyel spondilartrit ulusal tedavi önerileri

HATEMİ G., AKAR S., AKDOĞAN A., ATAGÜNDÜZ M. P., ersözlü e. d., ESATOĞLU S. N., et al.
ulusal romatoloji dergisi , 2018 (Hakemli Dergi)

121. One year in review 2018: Behçet’s syndrome

Hatemi G., Seyahi E., Fresko İ., TALARICO R., Hamuryudan V.
Clinical and Experimental Rheumatology , cilt.36, sa.6, 2018 (SCI-Expanded, Scopus)

122. Considerations in designing and interpreting prevalence studies for Behcet syndrome

Hatemi G., Esatoglu S. N., Yurdakul S.
POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ , cilt.128, sa.3, ss.148-149, 2018 (SCI-Expanded, Scopus) Creative Commons License

123. Biomarkers in vasculitis.

Hatemi G., Esatoglu S. N., Yazici Y.
Current opinion in rheumatology , cilt.30, sa.1, ss.30-35, 2018 (SCI-Expanded, Scopus)

124. Method

Hatemi G.
TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.28, 2017 (SCI-Expanded, Scopus, TRDizin) Creative Commons License

125. Infliximab for uveitis of Behçet's syndrome: a trend for earlier initiation.

Guzelant G., Ucar D., Esatoglu S. N., Hatemi G., Ozyazgan Y., Yurdakul S., et al.
Clinical and experimental rheumatology , sa.6, ss.86-89, 2017 (SCI-Expanded, Scopus)

126. Developing a Core Set of Outcome Measures for Behçet Disease: Report from OMERACT 2016.

Hatemi G., Meara A., Ozguler Y., Direskeneli H., Mahr A., Easley E., et al.
The Journal of rheumatology , cilt.44, sa.11, ss.1750-1753, 2017 (SCI-Expanded, Scopus)

127. Certolizumab Pegol for Fatigue in Chronic Inflammatory Rheumatic Diseases: A Meta-Analysis

Ozguler Y., Esatoglu S. N., Karatemiz G., Unal A. U., Guzelant G., Dincses E., et al.
ARTHRITIS & RHEUMATOLOGY , cilt.69, 2017 (SCI-Expanded, Scopus)

128. Behçet's syndrome: providing integrated care.

Esatoglu S. N., Kutlubay Z., Ucar D., Hatemi I., Uygunoglu U., Siva A., et al.
Journal of multidisciplinary healthcare , cilt.10, ss.309-319, 2017 (Scopus) Creative Commons License

129. Long-term follow-up of secondary amyloidosis patients treated with tumor necrosis factor inhibitor therapy: A STROBE-compliant observational study.

Esatoglu S. N., Hatemi G., Ugurlu S., Gokturk A., Tascilar K., Ozdogan H.
Medicine , cilt.96, sa.34, 2017 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma

130. Behçet's disease: an MHC-I-opathy?

Hatemi G., KARATEMIZ G., YAZICI H.
Clinical and experimental rheumatology , ss.5, 2017 (SCI-Expanded, Scopus)

131. Apremilast for the treatment of Behcet's syndrome

Hatemi G., Yazici Y.
EXPERT OPINION ON ORPHAN DRUGS , cilt.5, sa.8, ss.677-681, 2017 (SCI-Expanded, Scopus)

132. Systemic vasculitis and the gut

Hatemi A. İ., Hatemi G., Çelik A. F.
CURRENT OPINION IN RHEUMATOLOGY , cilt.29, sa.1, ss.33-38, 2017 (SCI-Expanded, Scopus)

133. One year in review 2017: Behçet's syndrome

Hatemi G., Seyahi E., Fresko İ., Talarico R., Hamuryudan V.
Clinical and Experimental Rheumatology , cilt.35, 2017 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

134. Inadequate reporting of enrolled patient and study site characteristics, and inter-study site differences in randomized controlled trials: A systematic review in six leading medicine journals

Yurdakul S., Ayan G., Ozguler Y., Hatemi G., Ugurlu S., Seyahi E., et al.
European Journal of Internal Medicine , cilt.37, 2017 (SCI-Expanded, Scopus)

135. Re-initiation of biologics after the development of tuberculosis under anti-TNF therapy

Ozguler Y., Hatemi G., Ugurlu S., Seyahi E., Melikoglu M., Borekci Ş., et al.
RHEUMATOLOGY INTERNATIONAL , cilt.36, sa.12, ss.1719-1725, 2016 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

136. EARLIER USE OF INFLIXIMAB FOR THE UVEITIS OF BEHCET'S SYNDROME APPEARS TO BE ASSOCIATED WITH BETTER OUTCOME

Guzelant G., Ucar D., Hatemi G., Ozyazgan Y., Esatoglu N. S., Yurdakul S., et al.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY , cilt.34, sa.6, 2016 (SCI-Expanded, Scopus)

137. One year in review 2016: Belicet's syndrome

Hatemi G., Seyahi E., Fresko İ., TALARICO R., Hamuryudan V.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY , cilt.34, sa.6, 2016 (SCI-Expanded, Scopus)

138. Identifying Core Domains for BehcEt's Syndrome Trials: An International Physician and Patient Delphi Exercise

Meara A., Ozguler Y., Mahr A., Direskeneli H., Gül A., Yazici Y., et al.
ARTHRITIS & RHEUMATOLOGY , cilt.68, 2016 (SCI-Expanded, Scopus)

139. Associated Inflammatory Diseases in Takayasu's Arteritis: The Many Faces of a Disease

Esatoglu S. N., Celik A. M., UÇAR D., Celik A. F., UĞURLU S., HATEMİ G., et al.
ARTHRITIS & RHEUMATOLOGY , cilt.68, 2016 (SCI-Expanded, Scopus)

140. Fecal Calprotectin Level Is Useful in Identifying Active Disease in Behcet's Syndrome Patients with Gastrointestinal Involvement: A Controlled Study

Esatoglu S. N., Hatemi I., Ozguler Y., Hatemi G., Uzun H., Celik A. F., et al.
ARTHRITIS & RHEUMATOLOGY , cilt.68, 2016 (SCI-Expanded, Scopus)

141. Diagnostic Criteria as Separate From Classification Criteria: A Perpetual Motion Machine? Comment on the Article by Aggarwal et al.

Yazici H., Hatemi G., YAZICI Y.
Arthritis care & research , cilt.68, ss.1049, 2016 (SCI-Expanded, Scopus) Creative Commons License

142. Recommendations in the American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis Related to the Use of Biologic Agents in Patients With a History of Cancer Need Reconsideration: Comment on the Article by Singh et al.

YAZICI H., OZGULER Y., Hatemi G., YAZICI Y.
Arthritis & rheumatology (Hoboken, N.J.) , cilt.68, ss.1315-6, 2016 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma

143. Characteristics, Treatment, and Long-Term Outcome of Gastrointestinal Involvement in Behcet’s Syndrome

HATEMİ A. İ., ESATOĞLU S. N., HATEMİ G., ERZİN Y. Z., YAZICI H., ÇELİK A. F.
MEDICINE , cilt.95, 2016 (SCI-Expanded, Scopus)

144. Characteristics Predicting Tuberculosis Risk under Tumor Necrosis Factor-α Inhibitors: Report from a Large Multicenter Cohort with High Background Prevalence.

Kisacik B., Pamuk O. N., Onat A. M., Erer S. B., Hatemi G., Ozguler Y., et al.
The Journal of rheumatology , cilt.43, sa.3, ss.524-9, 2016 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

145. Management of Behçet's syndrome.

Ozguler Y., Hatemi G.
Current opinion in rheumatology , cilt.28, sa.1, ss.45-50, 2016 (SCI-Expanded, Scopus)

146. Highlights of the 17th International Conference on Behçet's syndrome

ESATOĞLU S. N., HATEMİ G., Leccese P., Olivieri I.
Clinical and Experimental Rheumatology , cilt.34, ss.3-9, 2016 (SCI-Expanded, Scopus)

147. Current Status, Goals, and Research Agenda for Outcome Measures Development in Behçet Syndrome: Report from OMERACT 2014.

Hatemi G., Ozguler Y., Direskeneli H., Mahr A., GÜL A., LEVI V., et al.
The Journal of rheumatology , cilt.42, sa.12, ss.2436-41, 2015 (SCI-Expanded, Scopus) Creative Commons License

148. Update on Outcome Measure Development for Large Vessel Vasculitis: Report from OMERACT 12

AYDIN S. Z., DIRESKENELI H., SREIH A., ALIBAZ-ONER F., GÜL A., KAMALI S., et al.
JOURNAL OF RHEUMATOLOGY , cilt.42, sa.12, ss.2465-2469, 2015 (SCI-Expanded, Scopus) Creative Commons License

149. Ocular Involvement of Behcet's Syndrome: a Comprehensive Review

Ozyazgan Y., Ucar D., Hatemi G., Yazici Y.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY , cilt.49, sa.3, ss.298-306, 2015 (SCI-Expanded, Scopus)

150. TNF-alpha antagonists and thalidomide for the management of gastrointestinal Behçet's syndrome refractory to the conventional treatment modalities: a case series and review of the literature

Hatemi A. İ., Hatemi G., Pamuk Ö. N., Erzin Y. Z., Çelik A. F.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY , cilt.94, sa.6, ss.129-137, 2015 (SCI-Expanded, Scopus)

151. A reappraisal of the association between Behcet's disease, myelodysplastic syndrome and the presence of trisomy 8: a systematic literature review

Esatoglu S. N., Hatemi G., Çelik A. F., Hatemi I., Soysal T., Çelik A. B.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY , cilt.33, sa.6, 2015 (SCI-Expanded, Scopus)

152. Suicidal ideation among patients with Behcet's syndrome

Saygin C., Uzunaslan D., Hatemi G., Hamuryudan V.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY , cilt.33, sa.6, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

153. Fragmented Qrs Patterns Do Not Correlate with the Degree of Lung and Skin Involvement in Patients with Systemic Sclerosis

Uzunaslan D., Saygin C., Kostek M., Özdemir M., Torun T., Altay S., et al.
ARTHRITIS & RHEUMATOLOGY , cilt.67, 2015 (SCI-Expanded, Scopus)

154. Assessing the Possible Association of Anti-TNF Use with New Neoplasms: An Important Methodological Consideration

Ozguler Y., Yazici Y., Hatemi G., Yazici H.
ARTHRITIS & RHEUMATOLOGY , cilt.67, 2015 (SCI-Expanded, Scopus)

155. Work Disability over Time in Behcet's Syndrome

Hatemi G., Tascilar K., Ozguler Y., Ugurlu S., Hamuryudan V.
ARTHRITIS & RHEUMATOLOGY , cilt.67, 2015 (SCI-Expanded, Scopus)

156. Restarting biologic agents in rheumatology patients who developed tuberculosis under TNF alpha-inhibitor treatment

Ozguler Y., Hatemi G., Ugurlu S., Seyahi E., Melikoglu M., Borekci S., et al.
EUROPEAN RESPIRATORY JOURNAL , cilt.46, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

157. Differences and similarities in rheumatology specialty training programmes across European countries

SIVERA F., RAMIRO S., CIKES N., DOUGADOS M., GOSSEC L., KVIEN T. K., et al.
ANNALS OF THE RHEUMATIC DISEASES , cilt.74, sa.6, ss.1183-1187, 2015 (SCI-Expanded, Scopus) Creative Commons License

158. Apremilast for Behçet's syndrome - A phase 2, placebo-controlled study

Hatemi G., Melikoglu M., Tunc R., Korkmaz C., Ozturk B. T., Mat C., et al.
New England Journal of Medicine , cilt.372, sa.16, ss.1510-1518, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

159. Double pylorus in a patient with Behçet's syndrome.

Hatemi A. İ., Hatemi G., Erzin Y. Z., Çelik A. F.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY , cilt.94, sa.6, ss.138-140, 2015 (SCI-Expanded, Scopus)

160. Fatigue is correlated with disease activity but not with the type of organ involvement in Behçet's syndrome: A comparative clinical survey

Buyuktas D., HATEMİ G., Yuksel-Findikoglu S., UĞURLU S., Yazici H., Yurdakul S.
Clinical and Experimental Rheumatology , cilt.33, ss.107-112, 2015 (SCI-Expanded, Scopus)

161. Currently Used Biologic Agents in the Management of Behcet's Syndrome

Saygin C., Uzunaslan D., Hatemi G.
CURRENT MEDICINAL CHEMISTRY , cilt.22, sa.16, ss.1976-1985, 2015 (SCI-Expanded, Scopus)

162. Effect of Apremilast on Quality of Life and Physical Function in Patients with Behcet's Syndrome.

Hatemi G., Melikoglu M., Tunc R., Korkmaz C., ÖZTÜRK B. T., Mat C., et al.
ARTHRITIS & RHEUMATOLOGY , cilt.66, 2014 (SCI-Expanded, Scopus)

163. Predictors of Quality of Life in Behcet's Syndrome.

Bozcan S., Ozguler Y., Tascilar K., Saygin C., Uzunaslan D., Hatemi G.
ARTHRITIS & RHEUMATOLOGY , cilt.66, 2014 (SCI-Expanded, Scopus)

164. Fatigue in Systemic Sclerosis

Uzunaslan D., Saygin C., Torun T., Özdemir M., Hatemi G.
ARTHRITIS & RHEUMATOLOGY , cilt.66, 2014 (SCI-Expanded, Scopus)

165. Anti-TNF Treatment for Refractory Vascular Involvement of Behcet's Syndrome.

Hamuryudan V., Seyahi E., Melikoglu M., Ugurlu S., Hatemi G., Yurdakul S., et al.
ARTHRITIS & RHEUMATOLOGY , cilt.66, 2014 (SCI-Expanded, Scopus)

166. Tuberculosis Reactivation Risk in Patients Treated with Tumor Necrosis Factor Alpha Inhibitors: A Turkish Experience with Higher Mortality and Different Background Diseases.

Kisacik B., Pamuk O., Onat A. M., Erer B., Hatemi G., Ozguler Y., et al.
ARTHRITIS & RHEUMATOLOGY , cilt.66, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

167. No appreciable decrease in fertility in Behcet's syndrome

Uzunaslan D., Saygin C., Hatemi G., Tascilar K., Yazici H.
RHEUMATOLOGY , cilt.53, sa.5, ss.828-833, 2014 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma

168. Current Status of Outcome Measure Development in Vasculitis

Merkel P. A., Aydin S. Z., Boers M., Cornell C., Direskeneli H., Gebhart D., et al.
JOURNAL OF RHEUMATOLOGY , cilt.41, sa.3, ss.593-598, 2014 (SCI-Expanded, Scopus) Creative Commons License

169. Outcome Measures Used in Clinical Trials for Behcet Syndrome: A Systematic Review

Hatemi G., Merkel P. A., Hamuryudan V., Boers M., Direskeneli H., Aydin S. Z., et al.
JOURNAL OF RHEUMATOLOGY , cilt.41, sa.3, ss.599-612, 2014 (SCI-Expanded, Scopus) Creative Commons License

170. Novel NLRP3/cryopyrin mutations and pro-inflammatory cytokine profiles in Behets syndrome patients

YÜKSEL Ş., Eren E., Hatemi G., Sahillioglu A. C., Gultekin Y., Demiroz D., et al.
INTERNATIONAL IMMUNOLOGY , cilt.26, sa.2, ss.71-81, 2014 (SCI-Expanded, Scopus) Creative Commons License

171. Predictors of Quality Of Life in Behcet's Syndrome

Bozcan S., Ozguler Y., Saygin C., Uzunarslan D., Tascilar E. K., Ugurlu S., et al.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY , cilt.32, sa.4, 2014 (SCI-Expanded, Scopus)

172. Biologics, colchicine, corticosteroids, immunosuppressants and interferon-alpha for Neuro-Behcet's Syndrome

Nava F., Ghilotti F., Maggi L., Hatemi G., Del Bianco A., Merlo C., et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS , sa.12, 2014 (SCI-Expanded, Scopus)

173. Tuberculosis Screening Before and During Treatment with Tumor Necrosis Factor Antagonists: Something Old, Something New

Hatemi G., Yazici H.
JOURNAL OF RHEUMATOLOGY , cilt.40, sa.12, ss.1938-1940, 2013 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma

174. Behcet's syndrome: a critical digest of the 2012-1213 literature

Hatemi G., Seyahi E., Fresko I., Hamuryudan V.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY , cilt.31, sa.3, 2013 (SCI-Expanded, Scopus)

175. Quantiferon-TB Gold in tube assay for the screening of tuberculosis before and during treatment with tumor necrosis factor alpha antagonists

Hatemi G., Melikoglu M., Ozbakir F., Tascilar K., Yazici H.
Arthritis Research and Therapy , cilt.14, sa.3, 2012 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma

176. The papulopustular lesion/arthritis cluster of Behcet's syndrome also clusters in families

Karaca M., Hatemi G., SÜT N., Yazici H.
RHEUMATOLOGY , cilt.51, sa.6, ss.1053-1060, 2012 (SCI-Expanded, Scopus) Creative Commons License

177. Should maintenance therapy be performed in ulcerative proctitis? How long should it be continued?

Yonal O., Hatemi G., Kaymakoglu S.
TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.23, ss.21-24, 2012 (SCI-Expanded, Scopus, TRDizin)

178. Do anti-TNF agents and combination treatment increase postoperative complication risk?

Yonal O., Hatemi G., Hamzaoglu H. O.
TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.23, ss.25-29, 2012 (SCI-Expanded, Scopus, TRDizin)

179. Behcet's syndrome and micro-organisms

Hatemi G., Yazici H.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY , cilt.25, sa.3, ss.389-406, 2011 (SCI-Expanded, Scopus)

180. Analyses of functional IL10 and TNF-alpha genotypes in Behcet's syndrome

Ates O., Dalyan L., Hatemi G., Hamuryudan V., Topal-Sarikaya A.
MOLECULAR BIOLOGY REPORTS , cilt.37, sa.7, ss.3637-3641, 2010 (SCI-Expanded, Scopus)

181. EFFICACY AND SAFETY OF TNF-ALPHA ANTAGONISTS IN THE MANAGEMENT OF BEHCET'S SYNDROME: A SYSTEMATIC REVIEW

Hatemi G., Hamuryudan V., Yurdakul S., Yazici H.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY , cilt.28, sa.4, 2010 (SCI-Expanded, Scopus)

182. WORK DISABILITY IN BEHCET'S SYNDROME

Hatemi G., Hamuryudan V., Tascilar K., Ugurlu S., Yazici H.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY , cilt.28, sa.4, 2010 (SCI-Expanded, Scopus)

183. COLCHICINE DOES NOT DECREASE THE NEED FOR IMMUNOSUPPRESSIVE USE AT LONG TERM IN BEHCET'S SYNDROME (BS)

Hamuryudan V., Hatemi G., Yurdakul S., Tascilar K., Mat C., Ozyazgan Y., et al.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY , cilt.28, sa.4, 2010 (SCI-Expanded, Scopus)

184. A COMPARATIVE STUDY OF CLINICAL, ENDOSCOPIC AND HISTOLOGIC FINDINGS IN PATIENTS WITH GASTROINTESTINAL BEHCET'S DISEASE AND CROHN'S DISEASE

Celik A. F., Hatemi I., Hatemi G., Satir E., Erzin Y., Sisman G., et al.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY , cilt.28, sa.4, 2010 (SCI-Expanded, Scopus)

185. EYE DISEASE IN JUVENILE PATIENTS WITH BEHCET'S SYNDROME

Ozyazgan Y., Seyahi E., Sarica A., Ugurlu S., Hatemi G., Yurdakul S., et al.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY , cilt.28, sa.4, 2010 (SCI-Expanded, Scopus)

186. ANTI-TNF THERAPY IN SEVERE UVEITIS OF BEHCET'S SYNDROME: REPORT OF 27 PATIENTS

Ugurlu S., Hamuryudan V., Ozyazgan Y., Seyahi E., Hatemi G., Yurdakul S., et al.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY , cilt.28, sa.4, 2010 (SCI-Expanded, Scopus)

187. THE PAPULOPUSTULAR LESION/ARTHRITIS CLUSTER OF BEHCET'S SYNDROME IS INDEPENDENTLY FAMILIAL

Karaca M., Hatemi G., Yazici H.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY , cilt.28, sa.4, 2010 (SCI-Expanded, Scopus)

188. CURRENT TRENDS IN THE MANAGEMENT OF BEHCET'S SYNDROME

Hatemi G., Hamuryudan V., Tascilar K., Yurdakul S., Fresko I., Melikoglu M., et al.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY , cilt.28, sa.4, 2010 (SCI-Expanded, Scopus)

189. Genetic susceptibility to Beh double dagger et's syndrome is associated with NRAMP1 (SLC11A1) polymorphism in Turkish patients

Ates O., Dalyan L., Hatemi G., Hamuryudan V., Topal-Sarikaya A.
RHEUMATOLOGY INTERNATIONAL , cilt.29, sa.7, ss.787-791, 2009 (SCI-Expanded, Scopus)

190. Tumor necrosis factor-alpha and Interleukin-10 gene promoter polymorphisms in Turkish rheumatoid arthritis patients

Ates O., Hatemi G., Hamuryudan V., Topal-Sarikaya A.
CLINICAL RHEUMATOLOGY , cilt.27, sa.10, ss.1243-1248, 2008 (SCI-Expanded, Scopus)

191. Atherosclerosis in Behcet's syndrome

Seyahi E., Ugurlu S., Cumali R., Balci H., Ozdemir O., Melikoglu M., et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM , cilt.38, sa.1, ss.1-12, 2008 (SCI-Expanded, Scopus)

192. Frequency of pathergy phenomenon and other features of Behçet`s syndrome among patients with inflammatory bowel disease

Hatemi A. İ., Çelik A. F., Hatemi G., Melikoğlu M., Arzuhal N., Mat C., et al.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY , cilt.50, sa.4, ss.91-95, 2008 (SCI-Expanded, Scopus)

193. THE LONG TERM PROGNOSIS OF BEHCET'S SYNDROME AMONG MEN WITH SKIN-MUCOSA INVOLVEMENT AT ONSET: RE-EVALUATION OF A COHORT OF PATIENTS ENROLLED IN A CONTROLLED TRIAL

Hamuryudan V., Hatemi G., Tascilar K., Ozyazgan Y., Seyahi E., Mat C., et al.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY , cilt.26, sa.4, 2008 (SCI-Expanded, Scopus)

194. INFLIXIMAB IN 10 PATIENTS WITH BEHCET'S OCULAR INVOLVEMENT

Ozyazgan Y., Sarica A., Seyahi E., Hatemi G., Yazici H.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY , cilt.26, sa.4, 2008 (SCI-Expanded, Scopus)

195. PPD REACTION IS NOT AUGMENTED IN BEHCET'S SYNDROME PATIENTS

Hatemi G., Melikoglu M., Sut N., Yazici H.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY , cilt.26, sa.4, 2008 (SCI-Expanded, Scopus)

196. Increased enthesopathy among Behcet's syndrome patients with acne and arthritis

Hatemi G., Fresko I., Tascilar K., Yazici H.
ARTHRITIS AND RHEUMATISM , cilt.58, sa.5, ss.1539-1545, 2008 (SCI-Expanded, Scopus)

197. Infliximab does not suppress the tuberculin skin test (purified protein derivative)

Hatemi G., Melikoglu M., Fresko I., Masatlioglu S., Tascilar K., Yazici H.
JOURNAL OF RHEUMATOLOGY , cilt.34, sa.3, ss.474-480, 2007 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

198. Successful management of cryoglobulinemia-induced leukocytoclastic vasculitis with thalidomide in a patient with multiple myeloma

Ar M. C., SOYSAL T., HATEMI G., SALIHOGLU A., YAZICI H., ULKU B.
ANNALS OF HEMATOLOGY , cilt.84, sa.9, ss.609-613, 2005 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

199. Bilateral inflammatory breast metastases of epithelial ovarian cancer

Ozguroglu M., Ersavasti G., Ilvan S., Hatemi G., Demir G., Demirelli F. H.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS , cilt.22, sa.4, ss.408-410, 1999 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma
Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 63

1. Mimickers of Nervous System Involvement Among Patients with Behcet's Syndrome

Arcan A., Uygunoglu U., Nas E. D., Caliskan E. B., KAYA GÜLEÇ Z. E., TÜTÜNCÜ M., et al.
Annual Meeting of the American-Academy-of-Neurology (AAN), California, Amerika Birleşik Devletleri, 5 - 09 Nisan 2025, cilt.104, (Özet Bildiri)

2. OCULAR AND PERIPHERAL BLOOD IMMUNE PHENOTYPES SUGGEST TRANSMIGRATION OF CD16+ MONOCYTES TO AN IMPORTANT EFFECTOR SITE IN BEHÇET’S DISEASE

Özgüler Y., Lın Z., Hatemi G., Cavers A., Nowatzky .
ACR Convergence 2023, California, Amerika Birleşik Devletleri, 10 - 15 Kasım 2023, ss.1-2, (Özet Bildiri)

3. AXIAL SPONDYLOARTHRITIS IN PATIENTS WITH GASTROINTESTINAL INVOLVEMENT OF BEHÇET SYNDROME

Esatoğlu S. N., Öz A., Hatemi A. İ., Çelik A. F., Uçar D., Adaletli İ., et al.
American College of Rheumatology, California, Amerika Birleşik Devletleri, 10 - 15 Kasım 2023, cilt.75, ss.3067-3068, (Özet Bildiri)

4. Long-term Safety of Apremilast From a Pooled Analysis of 15 Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Oral Ulcers Associated With Behcet's Syndrome

Mease P. J., HATEMİ G., Paris M., Cheng S., Maes P., Zhang W., et al.
Annual Meeting of the American-Academy-of-Dermatology (AAD), Louisiana, Amerika Birleşik Devletleri, 17 - 21 Mart 2023, (Özet Bildiri)

5. TOCILIZUMAB TREATMENT IN SEVERE AND REFRACTORY BEHÇET’S SYNDROME: A CASE SERIES

Toker Dinçer Z., Yurttaş B., Esatoğlu S. N., Uçar D., Uygunoğlu U., Uğurlu S., et al.
2023 EULAR European Congress of Rheumatology, Milan, İtalya, 31 Mayıs - 03 Haziran 2023, sa.8552665, ss.1-3, (Özet Bildiri)

6. Vessel Wall nflammation Detected With Superb Microvascular Imaging in Behçet Syndrome

Özgüler Y., Kayadibi Y., Melikoğlu M., Esatoğlu S. N., Kimyon U., Kalyoncu Uçar A., et al.
EULAR 2023 European Congress of Rheumatology , Milan, İtalya, 31 Mayıs - 03 Haziran 2023, sa.8568497, ss.1-2, (Özet Bildiri)

7. FREQUENCY OF TUBERCULOSIS AND ASSOCIATED RISK FACTORS IN PATIENTS WITH BEHÇET’S SYNDROME

Yıldırım M., Esatoğlu S. N., Özgüler Y., Melikoğlu M., Fresko İ., Hamuryudan V., et al.
2023 EULAR European Congress of Rheumatology , Milan, İtalya, 31 Mayıs - 03 Haziran 2023, sa.8552625, ss.1-3, (Özet Bildiri)

8. Outcome of Vascular lnvolvement of Behçet Syndrome Treated with I nfliximab: A Retrospective Cohort Study

Hatemi G., Tükek B. N., Esatoğlu S. N., Özgüler Y., Taflan S. S., Melikoğlu M., et al.
ACR Convergence 2022, Pennsylvania, Amerika Birleşik Devletleri, 10 - 14 Kasım 2022, ss.1-2, (Özet Bildiri)

9. Dissection of Ocular and Peripheral Blood I mmune Phenotypes Suggests Preferential Transmigration of CD16+ Monocytes to Effector Sites in Behçet's Disease

Özgüler Y., Lın Z., Cavers A., Hatemi G., Manches O.
ACR Convergence 2022 , Pennsylvania, Amerika Birleşik Devletleri, 10 - 14 Kasım 2022, sa.8573631, ss.1-3, (Özet Bildiri)

10. Validation of Behçet's Disease Overall Damage lndex (BODI) for Retrospective Studies and a Proposal for Modification

Özgüler Y., Yağız Özoğul Y., Uçar D., Uygunoğlu U., Kutlubay Z., Hamuryudan V., et al.
ACR Convergence 2022 , Pennsylvania, Amerika Birleşik Devletleri, 10 - 14 Kasım 2022, ss.1-2, (Özet Bildiri)

11. Venous Halo Sign Detected with Superb Microvascular lmaging in Behçet Syndrome

Özgüler Y., Kayadibi Y., Melikoğlu M., Esatoğlu S. N., Üstündağ A., Kimyon U., et al.
ACR Convergence 2022, Pennsylvania, Amerika Birleşik Devletleri, 10 - 14 Kasım 2022, ss.1-3, (Özet Bildiri)

12. Behçet sendromu hastalarında geçirilmiş aktif tüberküloz ve latent tüberküloz sıklığı

Özgüler Y., Yıldırım ., Ahadzade A., Esatoğlu S. N., Melikoğlu M., Fresko İ., et al.
22. Ulusal Romatoloji Kongresi, Antalya, Türkiye, 26 - 30 Ekim 2022, ss.4-5, (Özet Bildiri)

13. Behçet sendromunun vasküler tutulumunda infliksimab tedavisi sonuçları: Retrospektif bir kohort çalışması

Hatemi G., Tükek N. B., Esatoğlu S. N., Özgüler Y., Taflan S. S., Melikoğlu M., et al.
22. Ulusal Romatoloji Kongresi, Antalya, Türkiye, 26 - 30 Ekim 2022, ss.5-6, (Özet Bildiri)

14. Behçet sendromunda süper mikrovasküler görüntüleme ile venöz halo işareti

Özgüler Y., Kayadibi Y., Melikoğlu M., Esatoğlu S. N., Üstündağ A., Kimyon U., et al.
22. Ulusal Romatoloji Kongresi, Antalya, Türkiye, 26 - 30 Ekim 2022, ss.4-5, (Özet Bildiri)

15. Oküler ve periferik kan immün fenotiplerinin değerlendirilmesi ile Behçet sendromunda CD16+ monositlerinin efektör bölgelere tercihli göçünü düşündürmektedir

Özgüler Y., Lin Z., Hatemi G., Cavers A., Nowatzky J O.
22. ULUSAL ROMATOLOJİ KONGRESİ, Antalya, Türkiye, 26 - 30 Ekim 2022, ss.5-7, (Özet Bildiri)

16. ANCA ilişkili vaskülitlerde merkezi sinir sistemi tutulumu ve taklitçileri

Yağız Özoğul Y., Esatoğlu S. N., Özoğul M., Kızılkılıç O., Özgüler Y., Hamuryudan ., et al.
22. Ulusal Romatoloji Kongresi, Antalya, Türkiye, 26 - 30 Ekim 2022, ss.3-4, (Özet Bildiri)

17. ERAP1-mediated immunogenicity and immune-phenotypes in HLA-B51(+) Behcet's and Behcet's uveitis point to pathogenic CD8 T cell effector responses

Nowatzky J., Cavers A., Ozguler Y., Al-Obeidi A. F., Yurttas B., Zhong H., et al.
Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO), ELECTR NETWORK, 1 - 07 Mayıs 2020, cilt.61, (Özet Bildiri)

18. Improvements and correlations in oral ulcers, disease activity, and quality of life in Behcet syndrome patients treated with apremilast: A phase III randomized, double-blind, placebo-controlled study (RELIEF)

Hatemi G., Mahr A., Takeno M., Kim D., Melikoglu M., Cheng S., et al.
Annual Meeting of the American-Academy-of-Dermatology (AAD), Washington, Kiribati, 1 - 05 Mart 2019, cilt.81, (Özet Bildiri)

19. DISEASE COURSE AND COSTS OF A COHORT OF RHEUMATOID ARTHRITIS PATIENTS OVER A PERIOD OF 6 YEARS

Ayan G., Esatoglu S. N., Hatemi G., Hamuryudan V.
Annual European Congress of Rheumatology (EULAR), Madrid, İspanya, 12 - 15 Haziran 2019, cilt.78, ss.1577-1578, (Özet Bildiri)

20. MYCOPHENOLATE MOFETIL IN THE TREATMENT OF MAJOR ORGAN INVOLVEMENT OF PATIENTS WITH BEHCET'S SYNDROME

ESATOĞLU S. N., Cemre E., HAMURYUDAN V., ÖZYAZGAN Y., UÇAR D., KUTLUBAY Z., et al.
Annual European Congress of Rheumatology (EULAR), Madrid, İspanya, 12 - 15 Haziran 2019, cilt.78, ss.820, (Özet Bildiri)

21. EVIDENCE BASED RECOMMENDATIONS FOR THE MANAGEMENT OF ENTEROPATHIC ARTHRITIS: A RHEUMATOLOGY, GASTROENTEROLOGY COLLABORATIVE INITIATIVE

HATEMİ G., AKAR S., AKPINAR H., Atagunduz P., Bengi G., CAN G., et al.
Annual European Congress of Rheumatology (EULAR), Madrid, İspanya, 12 - 15 Haziran 2019, cilt.78, ss.881, (Özet Bildiri)

22. INITIAL MANIFESTATIONS AND OUTCOME OF PATIENTS WITH INCOMPLETE BEHCET'S SYNDROME

ESATOĞLU S. N., BİLGİN S., SULU C., HAMURYUDAN V., KUTLUBAY Z., UĞURLU S., et al.
Annual European Congress of Rheumatology (EULAR), Madrid, İspanya, 12 - 15 Haziran 2019, cilt.78, ss.428, (Özet Bildiri)

23. EFFICACY OF APREMILAST FOR ORAL ULCERS ASSOCIATED WITH ACTIVE BEHCET'S SYNDROME OVER 64 WEEKS: RESULTS FROM A PHASE III STUDY

Hatemi G., Mahr A., Takeno M., Kim D., Saadoun D., Direskeneli H., et al.
Annual European Congress of Rheumatology (EULAR), Madrid, İspanya, 12 - 15 Haziran 2019, cilt.78, ss.148-149, (Özet Bildiri)

24. THE OMERACT CORE DOMAIN SET FOR CLINICAL TRIALS IN BEHCET'S SYNDROME

Hatemi G., Meara A., Ozguler Y., Direskeneli H., Mahr A., Shea B., et al.
Annual European Congress of Rheumatology (EULAR), Madrid, İspanya, 12 - 15 Haziran 2019, cilt.78, ss.431, (Özet Bildiri)

25. A DECLINING TREND IN FREQUENCY OF SECONDARY AMYLOIDOSIS IN BEHCET'S SYNDROME

Esatoglu S. N., Hatemi G., Karatemiz G., Ozguler Y., Yurdakul S., Hamuryudan V., et al.
19th International Vasculitis and ANCA Workshop, Pennsylvania, Amerika Birleşik Devletleri, 7 - 10 Nisan 2019, cilt.58, (Özet Bildiri)

26. IMPROVEMENTS AND CORRELATIONS IN ORAL ULCERS, DISEASE ACTIVITY, AND QOL IN BEHCET'S SYNDROME PATIENTS TREATED WITH APREMILAST: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY

HATEMİ G., Mahr A., Takeno M., Kim D., Melikoglu M., Cheng S., et al.
19th International Vasculitis and ANCA Workshop, Pennsylvania, Amerika Birleşik Devletleri, 7 - 10 Nisan 2019, cilt.58, ss.111, (Özet Bildiri)

27. WORK PRODUCTIVITY IS IMPAIRED IN PATIENTS WITH BEHCET'S SYNDROME

Serin N., Ozguler Y., Esatoglu S. N., Hamuryudan V., Hatemi G.
19th International Vasculitis and ANCA Workshop, Pennsylvania, Amerika Birleşik Devletleri, 7 - 10 Nisan 2019, cilt.58, (Özet Bildiri)

28. IMPROVEMENTS IN QUALITY OF LIFE IN BEHCET'S SYNDROME PATIENTS TREATED WITH APREMILAST: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY

HATEMİ G., Mahr A., Takeno M., Kim D., Melikoglu M., Cheng S., et al.
19th International Vasculitis and ANCA Workshop, Pennsylvania, Amerika Birleşik Devletleri, 7 - 10 Nisan 2019, cilt.58, (Özet Bildiri)

29. HYPERCOAGULABILITY AS A CAUSE OF THROMBOSIS IN BEHCET'S SYNDROME: A SYSTEMATIC REVIEW AND META-ANALYSIS

Guzelant G., Yurttas B., Esatoglu S. N., Hamuryudan V., Yazici H., Hatemi G.
19th International Vasculitis and ANCA Workshop, Pennsylvania, Amerika Birleşik Devletleri, 7 - 10 Nisan 2019, cilt.58, ss.139, (Özet Bildiri)

30. AORTIC INVOLVEMENT IN RELAPSING POLYCHONDITIS: A SYSTEMATIC REVIEW

Erdogan M., Esatoglu S. N., Hatemi G., Hamuryudan V.
19th International Vasculitis and ANCA Workshop, Pennsylvania, Amerika Birleşik Devletleri, 7 - 10 Nisan 2019, cilt.58, (Özet Bildiri)

31. INTERFERON-ALPHA FOR THE MANAGEMENT OF LOWER EXTREMITY DEEP VEIN THROMBOSIS IN BEHCET'S SYNDROME: A CASE SERIES

Ozguler Y., Hatemi G., Cetinkaya F., Tascilar K., Ugurlu S., Seyahi E., et al.
19th International Vasculitis and ANCA Workshop, Pennsylvania, Amerika Birleşik Devletleri, 7 - 10 Nisan 2019, cilt.58, (Özet Bildiri)

32. The Evaluation of Cytogenetics Results Obtained from Behçet Disease with Gastrointestınal Involment

YILMAZ Ş., ESATOĞLU S. N., Kuru D., SALİHOĞLU A., ÇIRAKOĞLU A., HATEMİ G., et al.
13th National Congress of Medical Genetics with International Participation, Antalya, Türkiye, 7 - 11 Kasım 2018, ss.30, (Özet Bildiri)

33. Could neurological involvement in Behcet's Disease occur atypically?

Siva A., Esatoglu S. N., Uygunoglu U., Ozguler Y., Hatemi G., Tutuncu M., et al.
70th Annual Meeting of the American-Academy-of-Neurology (AAN), Los-Angeles, Şili, 21 - 27 Nisan 2018, cilt.90, (Özet Bildiri)

34. A SYSTEMATIC LITERATURE REVIEW ON THE TREATMENT OF MAJOR ORGAN INVOLVEMENT OF BEHCET'S SYNDROME INFORMING THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF BEHCET'S SYNDROME

Ozguler Y., Leccese P., Christensen R., Esatoglu S. N., Olivieri I., Yazici H., et al.
18th International Vasculitis and ANCA Workshop, Tokyo, Japonya, 25 - 28 Mart 2017, cilt.56, ss.89, (Özet Bildiri)

35. FECAL CALPROTECTIN LEVEL LOOKS PROMISING IN IDENTIFYING ACTIVE DISEASE IN BEHCET'S SYNDROME PATIENTS WITH GASTROINTESTINAL INVOLVEMENT: A CONTROLLED AND PILOT STUDY

Esatoglu S. N., Hatemi I., Ozguler Y., Hatemi G., Uzun H., Celik A. F., et al.
18th International Vasculitis and ANCA Workshop, Tokyo, Japonya, 25 - 28 Mart 2017, cilt.56, ss.93, (Özet Bildiri)

36. EARLIER USE OF INFLIXIMAB FOR THE UVEITIS OF BEHCET'S SYNDROME APPEARS TO BE ASSOCIATED WITH BETTER OUTCOME

Guzelant G., Guzelant G., Ucar D., Hatemi G., Ozyazgan Y., Esatoglu S. N., et al.
18th International Vasculitis and ANCA Workshop, Tokyo, Japonya, 25 - 28 Mart 2017, cilt.56, ss.94, (Özet Bildiri)

37. IDENTIFYING CORE DOMAINS FOR BEHCETS SYNDROME TRIALS BY A DELPHI EXERCISE

Meara A. S., Ozguler Y., Mahr A., Direskineli H., Gül A., Yazici Y., et al.
18th International Vasculitis and ANCA Workshop, Tokyo, Japonya, 25 - 28 Mart 2017, cilt.56, ss.95, (Özet Bildiri)

38. PAPULOPUSTULAR LESIONS ACCORDING TO AGE, SEX AND LOCALIZATION IN BEHCET'S SYNDROME PATIENTS COMPARED HEALTHY AND DISEASED CONTROLS

Kutlubay Z., Ozguler Y., Hatemi G., Tascilar K., Mat C., Yazici H.
18th International Vasculitis and ANCA Workshop, Tokyo, Japonya, 25 - 28 Mart 2017, cilt.56, ss.90-91, (Özet Bildiri)

39. SYSTEMATIC REVIEW ON THE TREATMENT OF SKIN, MUCOSA AND JOINT INVOLVEMENT OF BEHCET'S SYNDROME INFORMING THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF BEHCET'S SYNDROME

Leccese P., Ozguler Y., Christensen R., Esatoglu S. N., Olivieri I., Yazici H., et al.
18th International Vasculitis and ANCA Workshop, Tokyo, Japonya, 25 - 28 Mart 2017, cilt.56, ss.89, (Özet Bildiri)

40. FACTORS ASSOCIATED WITH RENAL AND PATIENT SURVIVAL IN WEGENER GRANULOMATOSIS

Arslan E., Yalin S. F., Trabulus S., Hatemi G., Gulcicek S., Alagoz S., et al.
52nd Congress of the European-Renal-Association-European-Dialysis-and-Transplant-Assocation, London, Kanada, 28 - 31 Mayıs 2015, cilt.30, (Özet Bildiri)

41. Apremilast For The Treatment Of Behcet's Syndrome: A Phase II Randomized, Placebo-Controlled, Double-Blind Study

Hatemi G., Melikoglu M., Tunc R., KORKMAZ C., ÖZTÜRK B. T., Mat C., et al.
77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals, California, Amerika Birleşik Devletleri, 25 - 30 Ekim 2013, cilt.65, (Özet Bildiri)

42. Infliximab For Sight-Threatening and Refractory Uveitis Of Behcet's Syndrome

Hamuryudan V., Hatemi G., Ozyazgan Y., Ucar D., Yurdakul S., Seyahi E., et al.
77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals, California, Amerika Birleşik Devletleri, 25 - 30 Ekim 2013, cilt.65, (Özet Bildiri)

43. Systems Approach To The Study Of the Microbiome and Inflammatory Pathways In Oral Ulcer Tissue From Patients With Active Behcet's Syndrome (BS)

Sibley C., Hatemi G., Yazici Y., Liu Y., Brooks S., Yazici H., et al.
77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals, California, Amerika Birleşik Devletleri, 25 - 30 Ekim 2013, cilt.65, (Özet Bildiri)

44. Canakinumab In Patients With FMF

Ugurlu S., Seyahi E., Hatemi G., Hacioglu A., Ozdogan H.
77th Annual Meeting of the American-College-of-Rheumatology (ACR) / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals (ARHP), California, Amerika Birleşik Devletleri, 25 - 30 Ekim 2013, cilt.65, (Özet Bildiri)

45. Fertility In Behcet's Syndrome: Structured Interview In A Multidisciplinary Center

Saygin C., Uzunaslan D., Hatemi G., Tascilar K., Yazici H.
77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals, California, Amerika Birleşik Devletleri, 25 - 30 Ekim 2013, cilt.65, (Özet Bildiri)

46. Suicidal Ideation Among Patients With Behcet's Syndrome

Uzunaslan D., Saygin C., HATEMİ G., Tascilar K., Yazici H., HAMURYUDAN V.
77th Annual Meeting of the American-College-of-Rheumatology / 48th Annual Meeting of the Association-of-Rheumatology-Health-Professionals, California, Amerika Birleşik Devletleri, 25 - 30 Ekim 2013, cilt.65, (Özet Bildiri) Sürdürülebilir Kalkınma

47. Characteristics, Treatment and Outcome of Gastrointestinal Involvement in Behcet's Syndrome: Experience in A Dedicated Center

Hatemi I., Hatemi G., Erzin Y., Celik A. F., Yazici H.
Annual Scientific Meeting of the American-College-of-Rheumatology (ACR) and Association-of-Rheumatology-Health-Professionals (ARHP), Washington, Kiribati, 9 - 14 Kasım 2012, cilt.64, (Özet Bildiri)

48. DO Carriers of A MEFV Mutation Have Any Selective Advantage to A Pathogen Endemic In the Same Geography?

Ugurlu S., ENGİN A., Hatemi G., Ozgon G., Akyayla E., BAKIR M., et al.
75th Annual Scientific Meeting of the American-College-of-Rheumatology/46th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals, Illinois, Amerika Birleşik Devletleri, 4 - 09 Kasım 2011, cilt.63, (Özet Bildiri)

49. DOES CARRIERSHIP FOR FMF-ASSOCIATED MUTATIONS OFFER ANY ADVANTAGE IN CRIMEAN-CONGO HAEMORRHAGIC FEVER?

Ugurlu S., ENGİN A., Ozgon G., Hatemi G., Akyayla E., BAKIR M., et al.
Conference on Excellence in Rheumatology, İstanbul, Türkiye, 17 - 19 Şubat 2011, cilt.50, (Özet Bildiri)

50. ANKYLOSING SPONDYLITIS ASSOCIATED WITH TAKAYASU ARTERITIS

Yildirim S., Hatemi G., Yurdakul S., Fresko I., Ozdogan H.
Conference on Excellence in Rheumatology, İstanbul, Türkiye, 17 - 19 Şubat 2011, cilt.50, (Özet Bildiri)

51. THE FREQUENCY OF FIBROMYALGIA IS NOT INCREASED AMONG NURSES

Yurdakul S., Findikoglu S. Y., Hatemi G., Suzen S., Yazici H.
Conference on Excellence in Rheumatology, İstanbul, Türkiye, 17 - 19 Şubat 2011, cilt.50, (Özet Bildiri)

52. THE FREQUENCY OF NEPHROLITHIASIS AMONG PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER

Ozdogan H., Hatemi G., Ugurlu S., Ozguler Y., MASATLIOGLU S., ÇELİK S., et al.
Conference on Excellence in Rheumatology, İstanbul, Türkiye, 17 - 19 Şubat 2011, cilt.50, (Özet Bildiri)

53. WORK DISABILITY IN BEHCET'S SYNDROME

Hatemi G., Hamuryudan V., Tascilar K., Ugurlu S., Yazici H.
Conference on Excellence in Rheumatology, İstanbul, Türkiye, 17 - 19 Şubat 2011, cilt.50, (Özet Bildiri)

54. FOUR NOVEL MEFV GENE MUTATIONS IN A POPULATION WHERE THE PREVALENCE OF CRIMEAN-CONGO HEMORRHAGIC FEVER AND MEFV GENE CARRIER STATUS IS VERY HIGH

Ozgon G., ENGİN A., Hatemi G., Akyayla E., Ugurlu S., BAKIR M., et al.
Conference on Excellence in Rheumatology, İstanbul, Türkiye, 17 - 19 Şubat 2011, cilt.50, (Özet Bildiri) Creative Commons License

55. COLCHICINE DOES NOT DECREASE THE NEED FOR IMMUNOSUPPRESSIVE USE AT LONG TERM IN BEHCET'S SYNDROME

Hamuryudan V., Hatemi G., Yurdakul S., Mat C., Tascilar K., Ozyazgan Y., et al.
Conference on Excellence in Rheumatology, İstanbul, Türkiye, 17 - 19 Şubat 2011, cilt.50, (Özet Bildiri)

56. ANTI-TNF THERAPY IN SEVERE UVEITIS OF BEHCET'S SYNDROME: REPORT OF 27 PATIENTS

Ugurlu S., Hamuryudan V., Ozyazgan Y., Seyahi E., Hatemi G., Yurdakul S., et al.
Conference on Excellence in Rheumatology, İstanbul, Türkiye, 17 - 19 Şubat 2011, cilt.50, (Özet Bildiri)

57. V617F JAK2 mutations are not associated with thrombosis among patients with Behçet’s Syndrome.

AR C., HATEMİ G., EKİZOĞLU ERATAK S., SAÇLI S., BİLGEN H., BUYRU A. N., et al.
14th International Conference on Behçet`s Disease, Londra, Birleşik Krallık, 8 - 10 Temmuz 2010, (Özet Bildiri)

58. Tümör Nekroz Faktörü Alfa Antogonistleri ile Tedavi Quantıferon-TB Gold Testinin sonucunu etkilemez

HATEMİ G., MELİKOĞLU M., ÖZBAKIR F., Batumlu M., Taşçılar K., Çevirgen D., et al.
IX.Romatoloji Kongresi, Antalya, Türkiye, 11 - 15 Ekim 2008, ss.120, (Tam Metin Bildiri)

59. Quantiferon-TB gold blood test in rheumatoid arthritis patients using TNF-alpha antagonists

Hatemi G., Melikoglu M., Tascilar K., Batumlu M., Ozbakir F., Cevirgen D., et al.
72nd Annual Scientific Meeting of the American-College-of-Rheumatology/43rd Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals, San-Francisco, Kostarika, 24 - 29 Ekim 2008, cilt.58, (Özet Bildiri)

60. Effect of immunosuppressive treatment on skin pathergy reaction in Behcet's disease

Tascilar K., Melikoglu M., Baran A., Gogus F., Hatemi G., Yazici H.
72nd Annual Scientific Meeting of the American-College-of-Rheumatology/43rd Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals, San-Francisco, Kostarika, 24 - 29 Ekim 2008, cilt.58, (Özet Bildiri)

61. The MEFV gene 3 '-UTR alu repeat Polymorphisms in patients with familial Mediterranean

Ustek D., Ekmekci C. G., Oku B., Cosan F., Cakiris A., Abaci N., et al.
72nd Annual Scientific Meeting of the American-College-of-Rheumatology/43rd Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals, San-Francisco, Kostarika, 24 - 29 Ekim 2008, cilt.58, (Özet Bildiri)

62. Behcet's syndrome (BS) patients with acne and arthritis (BS-AA) have more enthesopathy than BS patients without acne and arthritis (BS-nonAA).

Hatemi G., Fresko I., Tascilar K., Yazici H.
70th Annual Scientific Meeting of the American-College-of-Rheumatology/41st Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals, Washington, Kiribati, 10 - 15 Kasım 2006, cilt.54, (Özet Bildiri)

63. Tumor necrosis factor alpha antagonists in the treatment of secondary amyloidosis.

Hatemi G., Tascilar K., Yurdakul S., Ozdogan H.
70th Annual Scientific Meeting of the American-College-of-Rheumatology/41st Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals, Washington, Kiribati, 10 - 15 Kasım 2006, cilt.54, (Özet Bildiri)
Kitaplar 2

1. Behçet Syndrome

Yazıcı Y. (Editör), Hatemi G. (Editör), Seyahi E. (Editör), Yazıcı H. (Editör)
Springer Nature, İstanbul, 2020

2. Behçet Sendromu için Sık Kullanılan Değerlendirme Ölçütleri

Hatemi G., Özgüler Y.
Primer Vaskülitlerde Hastalık Aktivite ve Hasar İndeksleri OLGU ÖRNEKLERİ İLE PRATİKLER, Ömer Karadağ-, Editör, Bayt Yayınevi, Ankara, ss.40-43, 2019
Metrikler

Yayın

281

Yayın (WoS)

240

Yayın (Scopus)

196

Atıf (WoS)

4613

H-İndeks (WoS)

31

Atıf (Scopus)

5325

H-İndeks (Scopus)

32

Atıf (Scholar)

14

H-İndeks (Scholar)

2

Atıf (TrDizin)

1

H-İndeks (TrDizin)

1

Atıf (Diğer Toplam)

1

Proje

8

Tez Danışmanlığı

8

Açık Erişim

42
BM Sürdürülebilir Kalkınma Amaçları
SDG 1: AMAÇ 1: YOKSULLUĞA SON
SDG 3: AMAÇ 3: SAĞLIKLI BİREYLER
SDG 8: AMAÇ 8: İNSANA YAKIŞIR İŞ VE EKONOMİK BÜYÜME
SDG 9: AMAÇ 9: SANAYİ, YENİLİKÇİLİK VE ALTYAPI
SDG 10: AMAÇ 10: EŞİTSİZLİKLERİN AZALTILMASI
SDG 16: AMAÇ 16: BARIŞ VE ADALET
SDG 17: AMAÇ 17: AMAÇLAR İÇİN ORTAKLIKLAR